Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Sales | 75 | 75 | 75 | 75 | 75 |
| Gross Profit | 75 | 75 | 75 | 75 | 75 |
| Operating Expenses | 21,861 | 18,843 | 16,663 | 15,250 | 13,922 |
| Operating Income | -21,786 | -18,768 | -16,588 | -15,175 | -13,847 |
| Interest Expense | 356 | 390 | 279 | 165 | 336 |
| Other Income | 48 | -17 | 62 | -62 | -29 |
| Pre-tax Income | -22,094 | -19,175 | -16,805 | -15,402 | -14,212 |
| Net Income Continuous | -22,094 | -19,175 | -16,805 | -15,402 | -14,212 |
| Net Income | $-22,094 | $-19,175 | $-16,805 | $-15,402 | $-14,212 |
| EPS Basic Total Ops | -0.85 | -0.81 | -0.71 | -0.65 | -0.02 |
| EPS Basic Continuous Ops | -0.84 | -0.81 | -0.71 | -0.65 | -0.03 |
| EPS Diluted Total Ops | -0.85 | -0.81 | -0.71 | -0.65 | -0.02 |
| EPS Diluted Continuous Ops | -0.84 | -0.81 | -0.71 | -0.65 | -0.03 |
| EBITDA(a) | $-21,184 | $-18,021 | $-15,916 | $-14,600 | $-13,250 |